The metabolic consequences of imatinib mesylate: Changes on glucose,lypidic and bone metabolism |
| |
| Authors: | Massimo Breccia Giuliana Alimena |
| |
| Institution: | 1. The University of Texas MD Anderson Cancer Center, Houston, TX, USA;2. University of Campinas, Distrito de Barao Geraldo, Campinas, Brazil;3. Hospital de Especialidades CMN La Raza, Instituto Mexicano del Seguro Social, Seris y Zaachila s/n, Colonia La Raza, Mexico, DF, Mexico;4. Banco Municipal de Sangre, Dpt. Clinicas Hematologicas, Hemato-Oncologia, Esq Pirineos, Caracas, DC, Venezuela;5. Hospital Britanico, Buenos Aires, Argentina;6. The Gujarat Cancer and Research Institute, Ahmedabad, India;7. Peking University People''s Hospital, Peking University Institute of Hematology, Beijing, China;8. Kidwai Memorial Institute of Oncology, Bangalore, India;9. HCG Curie Centre of Oncology, Bangalore, India;10. Russian Research Institute of Hematology and Transfusiology, St Petersburg, Russia;11. Universidade Federal de São Paulo, Hospital Santa Marcelina, São Paulo, Brazil;12. Shanghai Ruijin Hospital, Shanghai, China;13. Department of Haematology, Jagiellonian University Medical College, Kraków, Poland;14. University of São Paulo Medical School, São Paulo, Brazil;15. Guangzhou KingMed Center for Clinical Laboratory Co, Ltd, Guangzhou, Guangdong, China;p. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;q. Novartis Healthcare Pvt Ltd, Raheja Mind Space, Hitech City Madhapur/Hyderabad, Rangareddy, India;r. Novartis Pharma SAS, Oncology Global Development & Global Medical Affairs, France;s. Charité - University of Medicine Berlin, Campus Virchow-Klinikum, Medizinische Klinik mS, Hämatologie und Onkologie, Berlin, Germany;1. HRB Clinical Research Facility, National University of Ireland, Galway, Ireland;2. Leukemia Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, USA;3. Chaim Sheba Medical Center, Tel Hashomer, Israel;4. Center for Cancer Research and Cell Biology, Queens University, Belfast, Northern Ireland, United Kingdom;5. Division of Oncology and Hematology, Charité Universitätsmedizin Berlin, Berlin, Germany;6. Department of Hematology, St. James''s Hospital, Dublin, Ireland;7. Molecular Diagnostics Laboratory, University of Texas Health Science Center San Antonio, San Antonio, USA;8. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;9. Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA;1. CRCINA, Team SOAP, Inserm, CNRS, Université de Nantes, Université d''Angers, France;2. Institut de Cancerologie de l''Ouest, Rene Gauducheau, Saint-Herblain, France;1. Department of Respiratory Medicine, Mater Misericordiae University Hospital, 56 Eccles Street, Dublin 7, Ireland;2. Faculty of Medicine, Paris-South University, 63 rue Gabriel Peri, 94276 Le Kremlin-Bicêtre cedex, France;3. AP-HP, DHU Thorax Innovation, Department of Respiratory Medicine, Bicêtre Hospital, 78 rue du General Leclerc, 94275 Le Kremlin-Bicêtre cedex, France;4. INSERM U999, LabEx LERMIT, 133 Avenue de la Resistance, 92350 Le Plessis-Robinson, France |
| |
| Abstract: | The therapeutic efficacy of imatinib mesylate is based on its specific inhibition of several tyrosine kinases (TKs) implicated in the disease pathogenesis. These enzymes include BCR/ABL in patients with chronic myeloid leukaemia, PDGF-R alpha and beta in patients with certain myeloproliferative disorders and dermatofibrosarcoma protuberans and c-KIT in patients with gastrointestinal tumors. Most patients tolerate the drug well and apparently no metabolic abnormalities are evidenced during treatment. However, different metabolic effects have been reported as a consequence of imatinib inhibition during treatment of patients with CML. The aim of this review is to report the changes caused by imatinib on glucose, lypidic and bone metabolism. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
